| 23.48 -0.22 (-0.93%) | 07-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.11 | 1-year : | 31.68 |
| Resists | First : | 24.93 | Second : | 27.12 |
| Pivot price | 24.61 |
|||
| Supports | First : | 21.37 | Second : | 17.78 |
| MAs | MA(5) : | 23.78 |
MA(20) : | 24.34  |
| MA(100) : | 25.95 |
MA(250) : | 22.65 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 26 |
D(3) : | 32.2 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 33.63 | Low : | 13.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRPO ] has closed above bottom band by 23.0%. Bollinger Bands are 20.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.81 - 24.93 | 24.93 - 25.03 |
| Low: | 22.25 - 22.41 | 22.41 - 22.54 |
| Close: | 23.26 - 23.5 | 23.5 - 23.69 |
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Thu, 16 Jul 2026
Precipio (PRPO) director receives 108-share stock grant for Q2-26 service - Stock Titan
Thu, 16 Jul 2026
Precipio, Inc. (PRPO) director gets 416-share stock grant for Q2 board fees - Stock Titan
Thu, 16 Jul 2026
Precipio, Inc. (PRPO) director takes stock in lieu of cash pay - Stock Titan
Thu, 16 Jul 2026
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy? - TradingView
Tue, 14 Jul 2026
Precipio Inc. (PRPO) Holds Steady at $24.0 as Consolidation Persists - Positive Gamma - dars.gov.et
Sun, 28 Jun 2026
Precipio, Inc.(NasdaqCM: PRPO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 12.5 (%) |
| Held by Institutions | 17.6 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.94 |
| Profit Margin | -3.6 % |
| Operating Margin | -21.3 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -7.2 % |
| Qtrly Rev. Growth | 36.2 % |
| Gross Profit (p.s.) | 6.3 |
| Sales Per Share | 14.43 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -54.61 |
| PEG Ratio | 0 |
| Price to Book value | 2.95 |
| Price to Sales | 1.62 |
| Price to Cash Flow | 53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|